China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple clinical studies for its olverembatinib (HQP1351) and three clinical studies for its lisaftoclax (APG-2575) at the 66th American Society of Hematology (ASH) annual meeting. These presentations highlight the company’s commitment to advancing treatments for various hematological malignancies.
Olverembatinib Clinical Study Results
Olverembatinib, a novel orally-administered tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma, is the first approved third-generation BCR-ABL inhibitor in China. It is jointly commercialized in China by Ascentage Pharma and Innovent Biologics. The ASH annual meeting will feature an oral presentation of the latest results of a clinical study for olverembatinib in second-line chronic phase chronic myeloid leukemia (CP-CML). Additionally, the latest results of overseas clinical trials for the drug and a study combining olverembatinib with APG-2575 in children with relapsed/refractory (R/R) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) will be published on a poster.
Lisaftoclax Clinical Study Data
Lisaftoclax is a novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage to treat patients with malignancies by selectively blocking the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. The ASH meeting will also include an oral presentation of the latest data from a Phase I/II clinical study for lisaftoclax in recurrent/refractory (R/R) multiple myeloma (MM) or immunoglobulin light chain (AL) amyloidosis.- Flcube.com
